Tevogen Bio Holdings Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Tevogen Bio Holdings Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for TVGN-489 in Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company (Preclinical) using Cell Therapy.
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| Newsroom | Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company | Cell Therapy | n/a | Public pipeline row |
| TVGN-489 | n/a | Cell Therapy | Preclinical | Public pipeline row |
| COVID-19 | n/a | Cell Therapy | n/a | Public pipeline row |
| Development | n/a | n/a | n/a | Public pipeline row |
No public catalyst rows matched this view yet.
Estimated cash runway: Runway < 6 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| No public trial rows are loaded yet. | ||||
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.